Vaxart, Inc. (VXRT) stock
VXRTOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.48+0.02 (+5.04%)
Close on Oct 19, 2026Market cap $115.15MP/E 3.2Yield –
Vaxart operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Vaxart's operating income for the twelve months ending Jun 30, 2026 was $39.61M. For fiscal 2025 it was $18.07M. The highest annual figure on record is $18.07M in fiscal 2025.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $18.07M | – |
| FY2024 | Dec 31, 2024 | -$66.29M | – |
| FY2023 | Dec 31, 2023 | -$83.35M | – |
| FY2022 | Dec 31, 2022 | -$114.59M | – |
| FY2021 | Dec 31, 2021 | -$72.75M | – |
| FY2020 | Dec 31, 2020 | -$30.17M | – |
| FY2019 | Dec 31, 2019 | -$15.79M | – |
| FY2018 | Dec 31, 2018 | -$21.76M | – |
| FY2016 | Jun 30, 2016 | -$25.20M | – |
| FY2015 | Jun 30, 2015 | -$19.50M | – |
| FY2014 | Jun 30, 2014 | -$11.50M | – |
| FY2013 | Jun 30, 2013 | -$22.10M | – |
| FY2012 | Jun 30, 2012 | -$22.90M | – |
| FY2009 | Dec 26, 2009 | -$17.98M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026CQ2 2026 | Jun 30, 2026 | -$13.17M | – |
| Q1 FY2026CQ1 2026 | Mar 31, 2026 | $5.17M | – |
| Q4 FY2025CQ4 2025 | Dec 31, 2025 | $55.42M | – |
| Q3 FY2025CQ3 2025 | Sep 30, 2025 | -$7.81M | – |
| Q2 FY2025CQ2 2025 | Jun 30, 2025 | -$14.60M | – |
| Q1 FY2025CQ1 2025 | Mar 31, 2025 | -$14.94M | – |
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | -$11.49M | – |
| Q3 FY2024CQ3 2024 | Sep 30, 2024 | -$14.48M | – |
| Q2 FY2024CQ2 2024 | Jun 30, 2024 | -$16.26M | – |
| Q1 FY2024CQ1 2024 | Mar 31, 2024 | -$24.07M | – |
| Q4 FY2023CQ4 2023 | Dec 31, 2023 | -$16.90M | – |
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | -$17.82M | – |
| Q2 FY2023CQ2 2023 | Jun 30, 2023 | -$23.05M | – |
| Q1 FY2023CQ1 2023 | Mar 31, 2023 | -$25.57M | – |
| Q4 FY2022CQ4 2022 | Dec 31, 2022 | -$31.14M | – |
| Q3 FY2022CQ3 2022 | Sep 30, 2022 | -$29.43M | – |
| Q2 FY2022CQ2 2022 | Jun 30, 2022 | -$29.25M | – |
| Q1 FY2022CQ1 2022 | Mar 31, 2022 | -$24.78M | – |
| Q4 FY2021CQ4 2021 | Dec 31, 2021 | -$24.22M | – |
| Q3 FY2021CQ3 2021 | Sep 30, 2021 | -$17.25M | – |
| Q2 FY2021CQ2 2021 | Jun 30, 2021 | -$15.78M | – |
| Q1 FY2021CQ1 2021 | Mar 31, 2021 | -$15.51M | – |
| Q4 FY2020CQ4 2020 | Dec 31, 2020 | -$13.36M | – |
| Q3 FY2020CQ3 2020 | Sep 30, 2020 | -$7.59M | – |
| Q2 FY2020CQ2 2020 | Jun 30, 2020 | -$8.53M | – |
| Q1 FY2020CQ1 2020 | Mar 31, 2020 | -$694.00K | – |
| Q4 FY2019CQ4 2019 | Dec 31, 2019 | -$5.63M | – |
| Q3 FY2019CQ3 2019 | Sep 30, 2019 | -$4.71M | – |
| Q2 FY2019CQ2 2019 | Jun 30, 2019 | -$5.00M | – |
| Q1 FY2019CQ1 2019 | Mar 31, 2019 | -$448.00K | – |
| Q4 FY2018CQ4 2018 | Dec 31, 2018 | -$4.19M | – |
| Q3 FY2018CQ3 2018 | Sep 30, 2018 | -$5.88M | – |
| Q2 FY2018CQ2 2018 | Jun 30, 2018 | -$7.78M | – |
| Q1 FY2018CQ1 2018 | Mar 31, 2018 | -$3.92M | – |
| Q4 FY2016CQ2 2016 | Jun 30, 2016 | -$6.70M | – |
| Q3 FY2016CQ1 2016 | Mar 31, 2016 | -$5.20M | -572.7% |
| Q2 FY2016CQ4 2015 | Dec 31, 2015 | -$6.50M | – |
| Q1 FY2016CQ3 2015 | Sep 30, 2015 | -$6.70M | – |
| Q4 FY2015CQ2 2015 | Jun 30, 2015 | -$20.00M | – |
| Q3 FY2015CQ1 2015 | Mar 31, 2015 | $1.10M | – |
See a number that looks wrong?